Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

U.S. stocks performed positively again this week as investors assessed a flood of corporate earnings and the latest news ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Four states joined a federal lawsuit against CVS Pharmacy that claims the company caused state Medicaid programs to pay higher prices than non-Medicaid payers for prescription drugs. The states ...

Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug Meanwhile, CVS wasn’t the only one at the Wegovy dealmaking table with Novo this week. Tuesday, Novo announced that it’s ...

NEW YORK — CVS ... obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections. Coverage of these ...

Lilly CEO Dave Ricks said most customers affected by CVS's move would be smaller employers that do not tend to cover obesity drugs. Still, "it seems like the wrong idea to reduce choice," he said ...